Form FDA 3613b FDA 3613b Supplementary Information Certificate of a Pharmaceutica

Form Approved: OMB No. 0910-0498; Expiration Date: 10/31/2010

SUPPLEMENTARY INFORMATION
CERTIFICATE OF A PHARMACEUTICAL PRODUCT

Department of Health and Human Services
Food and Drug Administration
1. Requestor Information
Name

Address

Firm

Telephone number

Firm Tax ID code

FAX number

Email address

2. Section 1.0
Proprietary name
Dosage form

3. Section 1.1
Active ingredient
Amount per unit dose

Note: The information for this section may be provided in the approved product labeling and may be attached to the certificate. For certificate requests
for more than one country, provide a copy of the attachments for each country. Provide one copy of the attachments for FDA. Attachments are limited
to a total of 5 pages for CDER and 10 pages for CBER and CVM.

4. Section 2A.1 & 2A.2
Applicant name

Address

FDA product approval (AADA, ANDA, BLA/PLA, NADA, NDA)

Date of issue

Also, provide a copy of the approval letter as verification of the product license or NDA or NADA number and approval date.

5. Section 2A.3 or 2B.2
Status of Product license holder (mark appropriate item(s)):

Manufacturer

Packager and/or Relabeler

Neither

6. Facilities involved in the manufacturing of the exported product (A maximum of three facilities may be listed for CDER and four
facilities for CBER and CVM.)
Facility name (1)

Address

License number (if applicable)
Registration number

Date of most recent inspection

Facility name (2)

Address

License number (if applicable)
Registration number

CBER instructions begin on page 4.
FORM FDA 3613b (3/10)

Date of most recent inspection

CVM instructions begin on page 5.
Page 1 of 8

CDER instructions begin on page 6.
PSC Graphics (301) 443-1090

EF

6. Facilities involved in the manufacturing of the exported product (continued)
Facility name (3)

Address

License number (if applicable)
Registration number

Date of most recent inspection

Facility name (4)

Address

License number (if applicable)
Registration number

Date of most recent inspection

7. Section 2A.3.1
Do you want the manufacturing location(s) listed on the certificate?
Yes

No

8. Importing countries (list in columns)

9. Number of certificates requested:
10. Section 2B.3
For unapproved biological drugs, mark the category that indicates why authorization is lacking:
Not required

FORM FDA 3613b (3/10)

Not requested

Under consideration

Page 2 of 8

Refused

Department of Health and Human Services
Food and Drug Administration

EXPORTER’S CERTIFICATION STATEMENT
“CERTIFICATE OF A PHARMACEUTICAL PRODUCT”
for CBER and CVM

FIRM NAME

As the responsible official or designee of the company named above, I hereby certify to the United States Food and
Drug Administration that:
• the company, the manufacturing plant, and the product being exported, as identified in the Supplementary
Information, continue to be, to the best of my knowledge, in compliance with all applicable requirements of
the Federal Food, Drug, and Cosmetic Act;
• the product being exported has been manufactured, processed, packaged, and held in substantial conformity
with current good manufacturing practice requirements; and
• the product labeling provided with the Supplementary Information is a true and accurate representation of
the product labeling approved by the FDA.
SIGNATURE

DATE

NAME AND TITLE

Making or submitting false statements on any documents submitted to FDA may constitute violations of the
United States Code Title 18, Chapter 47, Section 1001 with penalties including up to $250,000 in fines and up to
5 years imprisonment.

Department of Health and Human Services
Food and Drug Administration

EXPORTER’S CERTIFICATION STATEMENT
“CERTIFICATE OF A PHARMACEUTICAL PRODUCT”
for CDER

The information, contained in this request for a Certificate of a Pharmaceutical Product, is true and accurate based
upon the current approved application or other legal basis permitting marketing of the product. We acknowledge
that any false or fictitious statements, made in the application, that are used by FDA to process the certificate, will
be in violation of the United States Code Title 18, Section 1001.
AUTHORIZATION TO RELEASE STATEMENT

We authorize the Food and Drug Administration to release this information in the certificate format. I understand that
we will be billed a fee for each certificate not to exceed $175.00. If you have any questions, or require additional
information regarding this correspondence, please call me at
(phone number).
SIGNATURE

DATE

NAME AND TITLE

FORM FDA 3613b (3/10)

Page 3 of 8

Department of Health and Human Services
Food and Drug Administration

EXPORT CERTIFICATION

Submission Requirements for Requesting Certificates for
Exporting Products to Foreign Countries (for CBER)
Background
Firms exporting products from the U.S. are often asked by foreign
customers or foreign governments to supply a certification relating
to products subject to the Federal Food, Drug, and Cosmetic Act
and other acts the Food and Drug Administration (FDA) administers. Under the FDA Export Reform and Enhancement Act of 1996
(the Act), FDA is authorized to issue certificates for drugs, animal
drugs, and devices within 20 days of receipt of a request for such a
certificate. A fee of up to $175 may be charged for each certificate
issued. In addition to issuing export certificates for approved or licensed products, the FDA will also issue export certificates for unapproved products that meet the requirements of Sections 801(e) or
802 of the Act.

General Instructions:
• The “Certificate to Foreign Government” is for the export of
products legally marketed in the United States. Certificate requests
should include the information listed in Supplementary Information – Certificate to Foreign Government Requests (PDF,
Text). Please ensure that the Exporter’s Certification Statement is
signed by a responsible official of the exporting firm and is enclosed with the certificate request. Please ensure that the appropriate Exporter Certification Statements for Certificate to Foreign
Government Requests for Human Cells, Tissues, and Cellular and
Tissue-Based Products (procured prior to May 25, 2005, or on or
after May 25, 2005) is signed by a responsible official of the
exporting firm and is enclosed with the certificate request.
• The “Certificate of Exportability” is for the export of products
not approved for marketing in the United States (unapproved products) that meet the requirements of Sections 801(e) or 802 of the
Act. Certificate requests should include the information listed in
Supplementary Information - Certificate of Exportability
Requests (PDF, Text). Please ensure that the Exporter’s Certification Statement is signed by a responsible official of the exporting firm and is enclosed with the certificate request.
• The “Certificate of a Pharmaceutical Product” conforms to
the format established by the World Health Organization (WHO)
and is intended for use by the importing country when the product in question is under consideration for a product license that
will authorize its importation and sale or for renewal, extension,
amending or reviewing a license. WHO Certificate requests should
include the information listed in Supplementary Information –
Certificate of a Pharmaceutical Product Requests (PDF, Text).
Please ensure that the Exporter’s Certification Statement is signed
by a responsible official of the exporting firm and is enclosed with
the certificate request.
• The “Non-clinical Research Use Only Certificate is for the export of a non-clinical research use only product, material, or
FORM FDA 3613b (3/10)

component that is not intended for human use which may be
marketed in, and legally exported from the United States under
the Federal Food, Drug, and Cosemetic Act. Certificate requests
should include the information listed in Supplementary Information - Non-clinical Research Use Only Certificate Requests
(PDF, Text). Please ensure that the Exporter’s Certification Statement is signed by a responsible official of the exporting firm and
is enclosed with the certificate request.
• Please type certificate requests or print clearly.
• In most cases, one product will be listed per certificate. However,
products that were approved under the same PLA / BLA, NDA,
PMA or 510(k) application or similar unapproved products may
be listed on the same certificate based on the available space for a
one page certificate. Certificate requests for listing multiple products will be evaluated on a case-by-case basis.
• If information is omitted in the application by the requester or if
clarification is needed on the supplied information, the requester
will be contacted via telephone or FAX. If the requester does not
provide the necessary information within 48 hours, the request for
certificates will be returned and will need to be resubmitted for
FDA review.
• Questions may be directed to the Import/Export Team at 301827-6201.
• Send the request and supporting documents to:
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
Division of Case Management
1401 Rockville Pike, Attention: HFM-624
Rockville, MD 20852-1448
or via FAX at 301-594-0940
• On October 1, 1996, CBER was given the authority to charge
$175 for the first two certificates and $85 for any subsequent certificates issued for the same product(s) in response to the same
certificate request. Please do not submit a check with your request, as FDA will bill you quarterly for issued certificates.
• You may enclose a completed FEDEX form to expedite the return of Certificates.
Issuance of a “Certificate to Foreign Government”, “Certificate
of Exportability” or “Certificate of a Pharmaceutical Product”
will not preclude regulatory action by FDA, if warranted,
against products covered by the Certificate.
A “Certificate to Foreign Government”, “Certificate of
Exportability” or “Certificate of a Pharmaceutical Product” is
issued by FDA solely for export purposes and may not be used
for domestic advertising.

Page 4 of 8

Department of Health and Human Services
Food and Drug Administration

INSTRUCTIONS FOR COMPLETION OF
APPLICATION FOR CERTIFICATES
(for CVM)
1. The Export Certificate to Foreign Governments is for the export
of products legally marketed in the United States. An application form must be completed and signed. The form is to be completed by the responsible head or designee of the exporting firm.
Please enclose labels for each product.
2. The Certificate of Exportability is for the export of products
unapproved for distribution and sale in the United States. The requestor must meet the requirements of Section 801(e) of the Act.
3. The “Certificate of a Pharmaceutical Product” conforms to
the format established by the World Health Organization (WHO)
and is intended for use by the importing country when the product in question is under consideration for a product license that
will authorize its importation and sale or for renewal, extension, amending or reviewing a license. WHO Certificate requests
should include the information listed in Supplementary Information – Certificate of a Pharmaceutical Product Requests.
Please ensure that the Exporter’s Certification Statement is
signed by a responsible official of the exporting firm and is enclosed with the certificate request.
4. If the requested information on the application form is not provided by the exporting firm or if clarification is needed on the
supplied information, the exporting firm will be contacted via
telephone or FAX. If the exporting firm does not provide the
necessary information within 48 hours, the request for certificates will be returned and will need to be resubmitted. You may
enclose a completed FEDEX form to expedite return of the Certificates. A certificate will be issued for each product.
FORM FDA 3613b (3/10)

5. Requests for certificates should be sent to:
Kim Bell
Center for Veterinary Medicine Division of
Compliance (HFV-235)
7519 Standish Place
Rockville, MD 20855
(240-276-9212- for inquiries)
6. The fee for preparing and issuing a single certificate is $175;
1st duplicate original $155 and $70 for each subsequent duplicate. No fee will be charged for animal food/feed products. Please
do not include the fee payment with your requests; the exporting firm will be billed quarterly.
7. The instructions and applications will be available on the CVM
Home Page (www.fda.gov/cvm/exportcertificate.htm).
PLEASE NOTE: Making or submitting false statements on
any documents submitted to FDA represents violations of the
United States Code, Title 18, Chapter 47, Section 1001 with
penalties including up to $10,000 in fines and up to 5 years
imprisonment.
Issuance of an Export Certificate for Approved Products or
Certificate of Exportability will not preclude regulatory action
by FDA, if warranted, against products covered by the Certificate. Certificates issued by the FDA are solely for export purposes and may not be used for domestic advertising.

Page 5 of 8

Department of Health and Human Services
Food and Drug Administration

CERTIFICATE OF A PHARMACEUTICAL PRODUCT
APPLICATION INSTRUCTIONS (for CDER)
INTRODUCTION

Ribbons

The Food and Drug Administration has historically issued various
types of certificates to firms exporting products to foreign countries. The Center for Drug Evaluation and Research (CDER) has
revised its procedures for the issuance of Certificates of a Pharmaceutical Product (examples are attached) for the following types of
requests:

The following colors are being used to designate the type of certificate requested:

• Drug products that are legally marketable in the U.S.;
• Products not authorized for sale in the U.S. which may be legally
exported to foreign governments (Certificate of a Pharmaceutical
Product for Export of an Unapproved Product under Sections 801
(e) or 802 of the FD&C Act); and
• Foreign Manufacturer (products manufactured outside of the U.S.).

GENERAL INFORMATION
A separate application must be made for each drug product. However, before preparing your application, please consult with the importing country to determine exactly what type of information is
being required for the certificate.
• Products approved with the same NDA number and the same dosage form, but with different potencies, can be processed on the
same certificate.
• Foreign names for the drug products may be included and noted
as “International Tradename” in the “Remarks” section of the
certificate.
• DO NOT submit applications in binders or put the attachments in
plastic sleeves.

Additional Information
To maintain conformity with the certificate format, additional information or statements must not exceed three lines of text. Text
that exceeds three lines must be typed on a separate 8½” x 11”
sheet of paper and will be attached to the certificate.

• Red will be affixed to all (regular) Certificates of Pharmaceutical
Product.
• Blue will be affixed to Certificates for Export of an Unapproved
Product.
• Yellow will be affixed to Certificates with Foreign Manufacturing
sites.

Fees
Under the FDA Export Reform and Enhancement Act of 1996, FDA
is authorized to charge a fee for certificates issued within 20 calendar days of receipt of an application. The fee, for each certificate,
shall not exceed $175.00. Do NOT send payment with the application; invoices are issued quarterly.
• Second certificate, for the same country, in
the same application ........................................................ $90.00
• Third and subsequent certificates, for the same country, in
the same application ........................................................ $40.00

Expiration Date
Certificates will expire 24 months from the date of notarization.
After expiration, a new application must be submitted. Certificates
cannot be reissued.

REQUIRED INFORMATION
An application for an export certificate must include the following
information:

Federal Tax Identification Number
To facilitate the billing process, the following information must be
included in all certificate applications:

Attachments

• Federal tax identification number

All attachments must be sent in duplicate. For certificate requests,
for more than one country, please provide the container label, package container, and package insert for each country as follows:

• Billing address and contact

An application for one country requires two sets of attachments
(one set for the certificate and one for our files).
• Requests for two or more countries require one set of attachments for each country, plus one additional copy for our files
(e.g., for two certificates, provide three sets of attachments; one
set for each certificate and one set for our files).
• Attachments must not exceed five pages per certificate.
FORM FDA 3613b (3/10)

Marketing Status in the Exporting Country (U.S.)
• Is the product currently marketed in the United States?
Yes or No.

Certification of Exportation from the U.S. for Foreign
Manufacturing Sites
Please include the following statement in the cover letter: “We certify that (Product Name) is manufactured and/or packaged in (Name

Page 6 of 8

Certificate of a Pharmaceutical Product – Application Instructions (for CDER) (Continued)

of Foreign Country) and is exported from the United States.” Unless
a product is sent from the U.S., directly to the requesting country, a
Certificate of a Pharmaceutical Product (CPP) will not be issued.

Country of Destination
Certificate requests, for multiple countries, can be made in one application. A certificate will be issued for each country, but only one
certificate number will be assigned per application.

U.S. Tradename (the drug product’s brand name)
or Generic Name
• The trade or generic name on the product as it is marketed in
the U.S.
• Labels with foreign tradenames must be accompanied by the U.S.
equivalent.

Container Label(s)
• An original sample of the current product label, approved for
marketing in the U.S., must be mounted on a plain sheet of 8½” x
11” paper. Loose, paper clipped, or labels in plastic sleeves will
not be accepted. (1 copy per certificate plus 1 copy for our files)
• One label for each potency requested must be submitted. (1 copy
per certificate plus 1 copy for our files)
• If the label is silk-screened onto the container, please send a copy
of the silkscreen or the art layout of the label mounted on a plain
sheet of 8½” x 11” paper. DO NOT send the container (e.g.,
bottles, tubes). (1 copy per certificate plus 1 copy for our files)
• To remain within the five-page attachment maximum, several
container labels can be mounted on one sheet of paper. Labels can
also be double mounted on both sides of the paper.

Package Container
• An original sample, of the current package container, must be
mounted on a plain sheet of 8½” x 11” paper. If the package container is a box, collapse it before mounting. (1 copy per certificate plus 1 copy for our files)
• If the carton is bulky, please send the art layout of the container
mounted on 8½” x 11” paper. (1 copy per certificate plus 1 copy
for our files)

Package Insert
An original sample of the current package insert must be mounted
on a plain sheet of 8½” x 11” paper. (1 copy per certificate plus 1
copy for our files)
NOTE: For OTC products, the product sample and promotional
literature are no longer needed.

Name and Address of Manufacturing Facility,
Including Zip Code

• Provide a brief explanation, and/or documentation (e.g., FDA Form
356 H), if there have been any changes in the corporate structure
or in the company name.

Marketing Authority
New drug and abbreviated new drug approval letters are considered
to be the only “license” to market a drug product. If the product
does not have an approval letter, provide the legal basis permitting
marketing of the product. Over-the-Counter drugs and those with
grandfathered status are marketed under OTC monographs and Compliance Program Guide (CPG 7132c.02), respectively.

NDA, ANDA, or AADA Approval Letter
• Copy of the original approval letter as verification of the NDA,
ANDA, or AADA number, approval date, application holder, product name, dosage form, and potency of the drug product. If the
NDA holder has changed, please provide the name of the new
application holder.
• Copy of supplemental approval letters for new dosage forms, new
potencies, new indications, and Rx to OTC switches. DO NOT
submit supplemental approval letters for new manufacturing sites
or stability studies.

Over-the-Counter (OTC)
• Provide the title and date of the applicable monograph. DO NOT
attach a copy of the publication.

Grandfathered Status
• Provide a statement addressing the grandfathered status of the
drug product.

Sections 801(e) and 802 of the Food, Drug, and
Cosmetic Act
• Export of unapproved drug products that are not authorized for
sale in the U.S. may be legally exported to foreign countries under § 801(e) and 802 of the FD&C Act.
• A copy of the product formulation, to be attached to the certificate, must be included with the application.

Status of Product-license Holder
The product-license holder is the name of the company that owns
the new drug or abbreviated new drug application. Please indicate,
in the cover letter, the name of the current product-license holder
of the NDA or ANDA. For purposes of complying with the WHO
scheme, the product-license holder is classified as one of the following:
• Manufacturer

• Include the name of the manufacturing site, with a complete street
address.
FORM FDA 3613b (3/10)

• Provide the registration number for the manufacturing facility.

• Packager/Labeler
• Neither (Distributor)

Page 7 of 8

Certificate of a Pharmaceutical Product – Application Instructions (for CDER) (Continued)

Status of Applicant
The applicant is the name of the firm or person who submits an
application for an export certificate. For purposes of complying
with the WHO scheme, the applicant is classified as one of the
following:
• Manufacturer

ACTIVE PHARMACEUTICAL INGREDIENTS (API)
and Excipients
The active pharmaceutical ingredient (API) is the bulk drug substance (raw material) that has not been processed into a final
dosage form (e.g., tablet, capsule).
• Provide an original sample of the current bulk container label, for
the API, mounted on a plain sheet of 8½” x 11” paper.

• Packager/Labeler
• Neither (Distributor)

• Export certificates are NOT issued for inactive ingredients (excipients).

Certification Statement

INCOMPLETE APPLICATIONS

The information contained in this request for a Certificate of a Pharmaceutical Product is true and accurate and based upon the current
approved application or other legal basis permitting marketing of
the product. We acknowledge that any false or fictitious statements
made in the application, which are used by FDA to process the certificate, will be in violation of the United States Code Title 18, Section 1001.

To obtain a certificate, the applicant must provide all required information. An application with incomplete information, or improperly
mounted labels, will be returned to the submitter.

Product Identification Statement (required for
unapproved products)
For certificate requests for unapproved drug products, a product
identification statement must be included affirming that the company and the product to be exported are in compliance with applicable provisions of the Act as amended by the FDA Reform
and Enhancement Act of 1996. This statement also identifies the
provision of Sections 801 or 802 of the FD&C Act permitting
export as follows:

CORRECTION OF ERRORS
• Errors made by FDA during the preparation of export certificates
will be corrected, at no cost to the applicant, within 45 days after
issuance.
• Errors made in the application, by the submitter, cannot be corrected. A new application must be submitted.

MAILING ADDRESS
Please include self-addressed return labels with your application
and mail it to the following address. Please note that we are only
able to accept FEDEX for overnight mailing of the export certificates.
Food and Drug Administration
Center for Drug Evaluation and Research
Export Certificate Program
10903 New Hampshire Avenue
Building 51, Room 4249
Silver Spring, MD 20993-0002

We certify that the product to be exported is in compliance with
the applicable provisions of § 801(e) and 802 of the Act as
amended by the FDA Reform and Enhancement Act of 1996.

Authorization to Release Information
Each application must include a statement authorizing release of
the information contained in the certificate and attachment(s) as
follows:

If additional information is needed, please call one of the following members of the Export Certificate Team: Betty McRoy at 301796-3218 or Marta E. Gonzalez-Piñeiro at 301-796-3283.

We authorize the Food and Drug Administration to release this
information in the certificate format. I understand that we will
be billed a fee for each certificate, not to exceed $175.00.

Paperwork Reduction Act Statement

[Applies equally to CBER, CDER, and CVM portions of this form.]
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for
reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and
reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection
of information, including suggestions for reducing this burden, to the address below.
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
1350 Piccard Drive, 420A
Rockville, MD 20850
An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it
displays a currently valid OMB control number.
FORM FDA 3613b (3/10)

Page 8 of 8